United States Antacids Market Overview, 2031

Key Insights

• According to the research report, "United States Antacids Market Outlook, 2031," published by Bonafide Research, the United States Antacids Market was valued at more than 2.69 Billion in 2025.
• While traditional fast-acting antacids like calcium carbonate and magnesium hydroxide remain everyday staples, the market is shifting toward dual-action and novel acid-reducing therapies. A major regulatory breakthrough came with the U.S. FDA approval of vonoprazan (Voquezna) a novel potassium-competitive acid blocker (P-CAB). Unlike standard proton pump inhibitors (PPIs) or basic antacids, P-CABs provide rapid, sustained acid suppression without requiring activation by food, giving healthcare providers a distinct new class for erosive GERD and severe acid-related disorders.
• Demand for over-the-counter (OTC) antacids is heavily fueled by high rates of lifestyle and chronic health conditions. According to CDC data, adult obesity prevalence in the U.S. sits at 40.3%. Furthermore, 5.9% of U.S. adults are diagnosed with peptic ulcers, and over 60 million Americans suffer from heartburn at least once a month. These health indicators represent a massive addressable consumer base seeking fast, accessible, non-prescription relief.
• Delivery format drives purchasing decisions, with solid dosage forms (chewables and tablets) leading due to convenience. However, liquid antacids maintain a significant presence, holding a 31.3% product demand share. Manufacturers are leveraging this by launching portable liquid shots, travel-friendly single-serve packs, and sugar-free liquid formulations to cater to aging demographics and consumers who prioritize immediate onset over portability.

Market Outlook

• E-commerce and digital pharmacy distribution platforms are playing an increasingly dominant role in driving growth. Retail pharmacies remain the primary offline touchpoint for instant relief, but online platforms allow brand loyalists to purchase bulk, subscription-based, or specialized OTC acid remedies directly to their homes.
• R Consumer preference is shifting toward combination products that target multiple symptoms simultaneously (such as pairing acid neutralizers with anti-gas agents like simethicone). Simultaneously, brand innovation is prioritizing clean-label lines featuring organic ingredients, natural soothing extracts (e.g., botanical additions), and formulations free from artificial dyes or synthetic fillers to appeal to wellness-focused demographics.
• The U.S. landscape is led by major pharmaceutical and consumer health giants including Haleon (makers of Tums), Bayer AG, Sanofi, Procter & Gamble (Rolaids), and Reckitt Benckiser, operating under oversight and industry advocacy provided by the Consumer Healthcare Products Association (CHPA) and the U.S. Food and Drug Administration (FDA).

Market Dynamics

Driver: Aging population & lifestyle-induced acid reflux
The aging U.S. population and high rates of obesity directly drive chronic gastrointestinal conditions such as GERD and acid indigestion. As the esophageal sphincter naturally weakens with age, older demographics rely more heavily on immediate-acting over-the-counter (OTC) antacids for routine symptom management.
Challenge: Long-term health risks & regulatory scrutiny
Prolonged or excessive use of mineral-based antacids presents significant health risks, including milk-alkali syndrome, rebound acidity, and calcium overdose (leading to kidney stones and metabolic alkalosis). Additionally, stringent FDA monitoring around safety, potential product recalls, and historical ingredient withdrawals (such as ranitidine) force manufacturers to continuously adjust formulations and warning labels.
Trend: Alternative formats & plant-based/OTC hybrids
Consumer preference is shifting away from traditional chalky tablets toward alternative delivery formats like gummies, soft-chews, and portable liquid shots. Furthermore, brands are increasingly launching hybrid products that combine traditional acid-neutralizing minerals with botanicals (like ginger or carom seeds) or probiotics to offer holistic digestive health benefits.

Procurement and Industry Impact

• Calcium carbonate serves as the primary raw material active ingredient in the market, accounting for 35.5% of active ingredient demand. Procurement teams face exposure to mineral mining supply chains and medical-grade refining costs.
• Solid tablets lead production at majority of the revenue volume, but fast-growing categories like gummies and soft-gels require procurement shifts toward specialized gelatin/pectin bases and moisture-barrier packaging.
• Retail pharmacies remain the primary offline supply channel, controlling 53.6% of antacid sales. This forces manufacturers to allocate substantial trade spend and shelf-space procurement allowances to secure prime placements in national pharmacy chains and mass retailers.

Segment Analysis

USA Antacids Market By Drug Class
• Acid neutralizers remain closely associated with rapid, on-demand relief because they directly neutralize existing stomach acid rather than primarily suppressing future acid production. Calcium carbonate, magnesium hydroxide, aluminum hydroxide and sodium bicarbonate represent important active-ingredient approaches. The segment benefits from strong consumer familiarity and suitability for occasional heartburn. Chewable tablets and liquid products allow consumers to self-treat symptoms without requiring a prescription. The FDA identifies conventional antacids as one of the three major OTC medication classes used for heartburn.
• PPIs occupy a distinct position because they are designed for frequent heartburn rather than immediate symptom relief. OTC PPIs are intended for heartburn occurring on 2 or more days per week, and the FDA notes that full effect can take 1–4 days. OTC use is generally limited to a 14-day course, up to three times per year. This creates a different purchasing pattern from traditional antacids: consumers are more likely to view PPIs as a short treatment regimen for recurring symptoms rather than an occasional rescue product.
• H2 antagonists bridge the gap between rapid-relief antacids and longer-acting PPIs. They reduce stomach-acid production and typically begin working within 1–3 hours, according to the FDA. Famotidine has become particularly important in the U.S. OTC landscape. The segment is also influenced by consumer demand for products that provide longer symptom control than conventional acid neutralizers while remaining suitable for episodic use.
• Pro-motility agents represent a more specialized segment because their therapeutic purpose is fundamentally different from simple acid neutralization. They target gastrointestinal movement and gastric emptying rather than merely reducing acidity. Consequently, their relevance is stronger in symptom patterns involving motility disturbances, delayed gastric emptying or reflux associated with impaired gastrointestinal movement. Their use is generally more clinically directed than conventional OTC antacid consumption.
• Combination formulations are increasingly relevant because consumers may experience multiple gastrointestinal symptoms simultaneously, such as heartburn accompanied by gas or acid-related discomfort. Products combining an antacid with an H2 antagonist or an anti-gas ingredient can provide a broader symptom-management proposition. Combination formulations also allow manufacturers to differentiate products in a mature OTC category by emphasizing multi-symptom convenience.

USA Antacids Market By Dosage Form
• Tablets and chewables are particularly suited to portable, immediate-use treatment. Chewable formats eliminate the need for water and are therefore convenient for consumers experiencing symptoms at work, while traveling or after meals. Chewables also make dosage communication relatively straightforward because each unit generally contains a defined quantity of active ingredient. The FDA specifically illustrates antacid tablets among OTC heartburn-treatment products.
• Liquid suspensions offer an important alternative for consumers who have difficulty swallowing tablets or prefer a liquid formulation. They can also provide a distinctive sensory experience and are commonly positioned for relatively fast symptom management. The liquid format requires greater attention to shaking, dosing accuracy, storage and packaging design, making product presentation an important competitive factor.
• Powder formulations provide flexibility in administration and can be designed for rapid dispersion after mixing. They are particularly interesting for consumers who prefer non-tablet formats. However, preparation requirements can make powders less convenient than ready-to-use liquids or chewables. Packaging therefore plays an important role in maintaining portability and preventing moisture exposure.
• Gels and syrup-like formulations emphasize easy swallowing and smooth administration. Their physical consistency can make them attractive to consumers who dislike tablets. This format can also support distinctive flavoring and sensory characteristics, which are important in an OTC category where repeat purchasing can be influenced by taste and perceived comfort.
• Gummies represent a newer consumer-oriented dosage concept within gastrointestinal self-care. Their appeal comes from familiar confectionery-style administration, portability and ease of consumption. However, gummies must balance palatability with appropriate active-ingredient delivery. This makes formulation technology particularly important because traditional antacid actives do not always translate easily into gummy formats.

USA Antacids Market By Indication
• GERD represents one of the most clinically significant indications supporting acid-control products in the United States. NIDDK estimates that approximately 20% of people in the U.S. have GERD, illustrating the broad population affected by chronic or recurring reflux. GERD-related treatment increasingly involves selecting therapy according to symptom frequency and severity. Traditional antacids can provide episodic relief, while H2 antagonists and PPIs are more relevant when acid suppression is required.
• Heartburn is one of the strongest drivers of consumer self-care because it is recognizable and can often be treated without an immediate clinical consultation. The FDA defines heartburn as a burning sensation generally occurring behind the breastbone or in the upper abdomen due to acidic stomach contents. This indication strongly supports OTC purchasing because consumers can associate the symptom directly with available products. The availability of antacids, H2 blockers and PPIs also creates a stepped-treatment environment based on symptom frequency.
• Peptic ulcer disease has a more medically oriented treatment pathway than routine heartburn. NIDDK estimates that approximately 1%-6% of people in the United States have peptic ulcers. The major causes include H. pylori infection and NSAID use, meaning acid suppression is only one component of appropriate management. Consequently, prescription acid-suppressive therapy and treatment of the underlying cause are important alongside symptomatic relief.
• The others category can encompass acid indigestion, dyspepsia and related upper-GI discomfort. This segment is characterized by relatively broad consumer interpretation of gastrointestinal symptoms. An important distinction is that occasional indigestion does not necessarily represent GERD. NIDDK notes that gastroesophageal reflux can occur occasionally without constituting GERD, whereas GERD involves repeated bothersome symptoms or complications.

USA Antacids Market By Distribution Channel
• Retail pharmacies remain strategically important because consumers can obtain OTC gastrointestinal products while simultaneously accessing pharmacist advice. This is especially valuable when consumers are uncertain whether to choose an antacid, H2 antagonist or PPI. The channel also supports impulse and symptom-driven purchases, particularly when consumers visit pharmacies for unrelated medicines or household healthcare products.
• Hospital pharmacies serve a more clinically supervised segment. Their relevance is greater for patients receiving treatment for diagnosed gastrointestinal conditions, hospitalized patients and individuals requiring medication management alongside other therapies. Hospital-based distribution is therefore less dependent on spontaneous OTC purchasing and more influenced by physician treatment protocols, formulary decisions and inpatient medication requirements.
• E-commerce has changed how consumers purchase gastrointestinal products by enabling price comparison, subscription purchasing, product reviews and multi-pack purchases.
• The online channel is particularly suited to recurring heartburn-management products because consumers can reorder products without visiting a physical pharmacy. It also provides manufacturers with opportunities to educate consumers through detailed product descriptions and usage information.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce